FineHeart

FineHeart aims to provide a simpler, physiologic left ventricular assist device without complications of current devices.

FineHeart announces success in a 30-day preclinical study of its implantable cardiac output system, ICOMS.

FineHeart completes a 30-day preclinical study of its miniaturized heart pump technology.

The FlowMaker is a hybrid pacemaker and cardiac assist device designed to restore normal heart contraction.

FineHeart plans human trials for its ICOMS Flowmaker, a physiological heart pump for muscular heart failure.

FineHeart’s team includes researchers, engineers, and cardiac surgeons working on a wireless-powered heart pump for severe heart failure.

FineHeart’s ICOMS Flowmaker system will be presented at the 2021 ASAIO conference in Washington, DC.

FineHeart targets 50,000 severe heart failure patients untreated by current LVADs, with a potential market of over $5 billion annually.

FineHeart seeks innovative professionals to advance treatments for severe heart failure.

FineHeart seeks a production technician for medical devices on a 6-month contract or temporary basis.

Arnaud Mascarell and Stéphane Garrigue co-founded FineHeart, with backgrounds in biomedical engineering and cardiology.

Arnaud Mascarell and Stéphane Garrigue co-founded FineHeart, bringing expertise in biomedical engineering and cardiology.

FineHeart’s leadership team includes Arnaud Mascarell, Stéphane Garrigue, Virginie Rivet, Guillaume Buc, and Sophie Jonquière.

FineHeart’s leadership includes medical and strategic experts, including founders Stéphane Garrigue and Arnaud Mascarell.

FineHeart designs wirelessly powered, implantable heart pumps to optimize cardiac output while preserving natural heart function.

FineHeart is a French company developing innovative cardiovascular medical devices, including the FlowMaker system.

FineHeart’s mission is to address unmet needs for patients with severe heart failure.